MPPE1 and neoplasm: For instance, systemic injection of the growth factor fms-like tyrosine kinase 3 ligand (Flt3L) has been shown in preclinical studies to cause expansion and activation of the cDC1 population, dramatically enhancing the clinical response to checkpoint and BRAF blockade and significantly delaying tumor growth (78).